Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Curr Drug Metab. 2019;20(13):1044-1052. doi: 10.2174/1389200220666191112145808.
Solid Lipid Nanoparticles (SLNs) possess unique in vivo features such as high resistivity, bioavailability, and habitation at the target site. Coating nanoparticles with polymers such as chitosan greatly affects their pharmacokinetic behavior, stability, tissue uptake, and controlled drug delivery. The aim of this study was to prepare and evaluate the biodistribution of 99mTc-labeled SLNs and chitosan modified SLNs in mice.
99mTc-oxine was prepared and utilized to radiolabel pre-papered SLNs or chitosan coated SLNs. After purification of radiolabeled SLNs (99mTc-SLNs) and radiolabeled chitosan-coated SLNs (99mTc-Chi-SLNs) using Amicon filter, they were injected into BALB/c mice to evaluate their biodistribution patterns. In addition, nanoparticles were characterized using Transmission Electron Microscopy (TEM), Fourier-transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray Powder Diffraction (XRD) and Dynamic Light Scattering (DLS).
99mTc-oxine with high radiochemical purity (RCP~100%) and stability (RCP > 97% at 24 h) was used to provide 99mTc-SLNs and 99mTc-Chi-SLNs with high initial RCP (100%). TEM image and DLS data suggest 99mTc- SLNs susceptibility to aggregation. To that end, the main portion of 99mTc-SLNs radioactivity accumulates in the liver and intestines, while 99mTc-Chi-SLNs sequesters in the liver, intestines and kidneys. The blood radioactivity of 99mTc-Chi-SLNs was higher than that of 99mTc-SLNs by 7.5, 3.17 and 3.5 folds at 1, 4 and 8 h post-injection. 99mTc- Chi-SLNs uptake in the kidneys in comparison with 99mTc-SLNs was higher by 37.48, 5.84 and 11 folds at 1, 4 and 8h.
The chitosan layer on the surface of 99mTc-Chi-SLNs reduces lipophilicity in comparison with 99mTc- SLNs. Therefore, 99mTc-Chi-SLNs are less susceptible to aggregation, which leads to their lower liver uptake and higher kidney uptake and blood concentration.
固体脂质纳米粒(SLNs)具有独特的体内特性,如高电阻、生物利用度和在靶部位的定植。用壳聚糖等聚合物对纳米粒进行涂层处理,会极大地影响其药代动力学行为、稳定性、组织摄取和控释药物传递。本研究旨在制备和评估 99mTc 标记的 SLNs 和壳聚糖修饰的 SLNs 在小鼠体内的分布情况。
用 99mTc-oxine 标记预制的 SLNs 或壳聚糖包被的 SLNs。用 Amicon 过滤器纯化放射性标记的 SLNs(99mTc-SLNs)和放射性标记的壳聚糖包被的 SLNs(99mTc-Chi-SLNs)后,将其注入 BALB/c 小鼠体内,以评估其体内分布模式。此外,还使用透射电子显微镜(TEM)、傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)、X 射线粉末衍射(XRD)和动态光散射(DLS)对纳米粒进行了表征。
用高放射化学纯度(RCP~100%)和稳定性(24 小时时 RCP>97%)的 99mTc-oxine 为 99mTc-SLNs 和 99mTc-Chi-SLNs 提供了初始 RCP(100%)。TEM 图像和 DLS 数据表明 99mTc-SLNs 容易聚集。为此,99mTc-SLNs 的大部分放射性活性积聚在肝脏和肠道中,而 99mTc-Chi-SLNs 则在肝脏、肠道和肾脏中蓄积。与 99mTc-SLNs 相比,99mTc-Chi-SLNs 在注射后 1、4 和 8 小时时血液中的放射性分别高出 7.5、3.17 和 3.5 倍。与 99mTc-SLNs 相比,99mTc-Chi-SLNs 在肾脏中的摄取量在 1、4 和 8 小时时分别高出 37.48、5.84 和 11 倍。
与 99mTc-SLNs 相比,99mTc-Chi-SLNs 表面的壳聚糖层降低了亲脂性。因此,99mTc-Chi-SLNs 不易聚集,导致其肝脏摄取减少,肾脏摄取和血液浓度增加。